Investigating how estrogen receptor gene fusions contribute to resistance in breast cancer treatment
Estrogen receptor fusions genes as drivers of endocrine resistance in breast cancer
This study is looking at how specific genetic changes in estrogen receptors might make some advanced breast cancer patients less responsive to anti-estrogen treatments, with the goal of finding better ways to help those who aren't getting the results they need from current therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-11045036 on NIH RePORTER |
What this research studies
This research focuses on understanding how certain genetic changes in estrogen receptors lead to resistance against anti-estrogen therapies in patients with advanced breast cancer. By analyzing tumor samples and using advanced sequencing techniques, the study aims to identify the prevalence of these genetic fusions and their impact on treatment outcomes. The researchers will also explore how these fusions behave in patient-derived organoids, which mimic the patient's cancer more closely than traditional cell lines. This approach could help in developing more effective treatment strategies for patients who do not respond to current therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with advanced estrogen receptor-positive breast cancer who have experienced resistance to anti-estrogen therapies.
Not a fit: Patients with early-stage breast cancer or those who have not undergone anti-estrogen therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with advanced breast cancer who have developed resistance to standard therapies.
How similar studies have performed: Previous research has shown promising results in identifying genetic markers of resistance in breast cancer, suggesting that this approach could yield valuable insights.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Lee, Adrian V — University of Pittsburgh at Pittsburgh
- Study coordinator: Lee, Adrian V
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.